Aortyx increased its capital with a seed fund of 650,000 € led by Genesis Ventures. This seed round started in February 2019, initially aiming for 300,000 €. The excitemtent from the investors and the updated cash needs made our round the 14th in Spain in 2019 and the highest without Venture Capitals nor Crowdfunding platforms.
Our CEO and co-founder, Jordi Martorell, states that achieving this round of funding is a recognition of the trust placed by our investors in our daily work and the main objective of Aortyx: saving lives.
This capital raise has been key to start animal testing and to fix our commercialization objective in 2024. Likewise, we have already started the industrialization process of our prototype and put in motion our quality management system to comply with ISO 13485.
Learn more in the following links: